- Home
- JEM vs TCRX Comparison
JEM vs TCRX Comparison
Compare JEM & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JEM
- TCRX
- Stock Information
- Founded
- JEM 2021
- TCRX 2018
- Country
- JEM Hong Kong
- TCRX United States
- Employees
- JEM N/A
- TCRX N/A
- Industry
- JEM
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- JEM
- TCRX Health Care
- Exchange
- JEM NYSE
- TCRX Nasdaq
- Market Cap
- JEM 81.7M
- TCRX 82.1M
- IPO Year
- JEM 2025
- TCRX 2021
- Fundamental
- Price
- JEM $3.72
- TCRX $1.82
- Analyst Decision
- JEM
- TCRX Strong Buy
- Analyst Count
- JEM 0
- TCRX 6
- Target Price
- JEM N/A
- TCRX $9.50
- AVG Volume (30 Days)
- JEM 137.1K
- TCRX 319.7K
- Earning Date
- JEM 01-01-0001
- TCRX 08-11-2025
- Dividend Yield
- JEM N/A
- TCRX N/A
- EPS Growth
- JEM 13.72
- TCRX N/A
- EPS
- JEM 0.05
- TCRX N/A
- Revenue
- JEM $11,285,111.00
- TCRX $4,421,000.00
- Revenue This Year
- JEM N/A
- TCRX $159.20
- Revenue Next Year
- JEM N/A
- TCRX N/A
- P/E Ratio
- JEM $88.34
- TCRX N/A
- Revenue Growth
- JEM 4.38
- TCRX N/A
- 52 Week Low
- JEM $3.05
- TCRX $1.02
- 52 Week High
- JEM $7.90
- TCRX $7.31
- Technical
- Relative Strength Index (RSI)
- JEM N/A
- TCRX 53.96
- Support Level
- JEM N/A
- TCRX $1.76
- Resistance Level
- JEM N/A
- TCRX $1.99
- Average True Range (ATR)
- JEM 0.00
- TCRX 0.12
- MACD
- JEM 0.00
- TCRX -0.01
- Stochastic Oscillator
- JEM 0.00
- TCRX 22.92
About JEM 707 CAYMAN HOLDINGS LIMITED
707 Cayman Holdings Ltd is a Hong Kong-based group that sells quality apparel products and provides supply chain management total solutions to its customers spanning from Western Europe, North America to the Middle East. Its comprehensive range of supply chain management total solutions includes market trend analysis, design and product development, sourcing, production management, quality control and logistics services, and its solutions encompass the total supply chain from conceptualizing the product, the selection of materials until the final delivery of finished apparel products to its customers at their nominated destinations, whether it be a designated port for shipment, its customer's warehouse or the end consumers.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.